Joseph Paul Eder, MD

Professor of Medicine (Medical Oncology)

Physician Biography

Dr. Eder is a graduate of Georgetown University School of Medicine, where he did a medical residency. He did fellowships in Medical Oncology at Georgetown and Dana-Farber Cancer Institute and Hematology/Oncology at Beth Israel Hospital

He became the principal clinical investigator of the Harvard UO1 Phase I program in 1995, uniting the clinical efforts at the DFCI, BWH, MGH and BIDMC. In 1998, He became the Clinical Director of the Experimental Therapeutics Program for the Dana-Farber/Harvard Cancer Center. In 2004 he assumed the responsibilities as the Clinical Director of the DFCI General Cancer Research Center at the Dana-Farber/ Brigham and Women’s Hospital.

Particular areas of past and present involvement include high dose chemotherapy, the modulation/ reversal of drug resistance, growth factors, vaccines, immune-oncology, signal transduction pathway inhibitors, cell cycle inhibitors, and molecularly targeted therapies/Precision Medicine. He has served on Scientific Committees of the AACR and the International Symposium on Drug Development

At AstraZeneca PLC 2007-2012, he was appointed to be the Medical Science Director for AstraZeneca’s Boston site, responsible for the medical and clinical aspects of development of agents from chemical lead identification through clinical proof of concept in phase II. He was a member of the Strategic Planning & Business Development as an ad hoc member and was the Global Disease Area Clinical Expert for Hematology. He joined the Yale Cancer Center in 2012 as Clinical Director of the Early Drug Development Program and Assistant Director of Experimental Therapeutics

Clinical Interests

  • Medical Oncology
  • Clinical Trials, Phase I as Topic

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Early Drug Development Program | Subset Medical Oncology Faculty

Yale Cancer Center

Yale Medicine

Board Certifications

  • Internal Medicine AB of Internal Medicine (1981)

  • Medical Oncology AB of Internal Medicine (1983)

  • Hematology (Internal Medicine) AB of Internal Medicine (1984)

Clinical Trials

Conditions Study Title
Anus, Bladder, Breast - Female, Breast - Male, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I An Open-label Randomized Two-arm Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY 1217389 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
Phase I A Multicenter, Dose-Escalation, Phase 1 Study of Samalizumab (ALXN6000) to Evaluate the Pharmacokinetics, Safety, and Tolerability in Patients With Advanced Cancer
Lung, Melanoma, skin Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Phase I A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Lung, Melanoma, skin, Phase I A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer and Melanoma
Kidney, Melanoma, skin A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Melanoma, skin A Phase 1b/2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
Phase I, Unknown Sites A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors
Breast - Female, Breast - Male, Lung, Pancreas, Phase I A Phase II Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Kidney, Melanoma, skin A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors
Bladder, Breast - Female, Breast - Male, Colon, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Digestive Organ, Other Female Genital, Other Urinary, Ovary, Rectum, Stomach, Phase I A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors
Anus, Colon, Pancreas, Rectum, Phase I A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Esophagus, Eye and Orbit, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors
Anus, Bladder, Breast - Female, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I, Unknown Sites A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors
Anus, Bladder, Breast - Female, Colon, Esophagus, Kidney, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Multiple Myeloma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Other Hematopoietic, Unknown Sites A Phase I Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Soft Tissue, Phase I A Phase I, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non Small Cell Lung Cancer, and Other B7H3 Expressing Cancers
Anus, Bladder, Breast - Female, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I, Unknown Sites A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0919 Administered With MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors
Anus, Bladder, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Mycosis Fungoides, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Phase I, Unknown Sites, Ill-Defined Sites A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors
Anus, Bladder, Breast - Female, Breast - Male, Colon, Esophagus, Kidney, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Other Hematopoietic, Phase I A Phase IB, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Edit this profile